Testosterone Concentrations and Sirolimus in Male Renal Transplant Patients

American Journal of Transplantation

Volumn 4, Issue 1, 2004, Pages 130-131

  Fritsche, Lutz ^a   Budde, Klemens ^a   Dragun, Duska ^a   Einecke, Gunilla ^a   Diekmann, Fritz ^a   Neumayer, Hans Hellmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Side effects; Sirolimus; Testosterone; Transplantation

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; RAPAMYCIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; FOLLICLE STIMULATING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROLACTIN; SIROLIMUS; TESTOSTERONE;

EID: 0742284031     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00279.x     Document Type: Article

References (11)

1. Ruygrok PN, Muller DW, Serruys PW. Rapamycin in cardiovascular medicine. Intern Med J 2003; 33: 103-109.
2. Macdonald AS. Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
3. Kahan BD, Stepkowski SM, Napoli KL et al. The development of sirolimus: the University Texas-Houston experience. Clin Transpl 2000; 14: 145-158.
4. Macdonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas and kidney transplantation. Transplant Proc 2003; 35 (Suppl.): S201-S208.
5. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804-808.
6. Giessing M, Fischer TJ, Deger S et al. Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. Transplant Proc 2002; 34: 1815-1816. (No Abstract available.)
7. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 1992; 6: 39-87.
8. Rapamune® FDA Pharmacology Review, NDA 21-083, approved 15 November 1999. US Food and Drug Administration, Center for Drug Evaluation and Research. http://www.fda.gov/cder/foi/nda/99/21083A_Rapamune_phrmr_pl.pdf
9. Elit L. CCI-779 Wyeth. Curr Opin Invest Drugs 2002; 3: 1249-1254.
10. Diemont WL, Vruggink PA, Meuleman EJ et al. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis 2000; 35: 845-851.
11. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83: 801-806.